FOXP3 and hemophilia A: Adoptively transferred FoxP3 expressing cells from FVIII immunized mice (FoxP3FVIII) were able to successfully prevent inhibitor formation in previously untreated hemophilia A mice and, when applied as combination therapy with a B-cell depleting antibody (anti-mCD20), were able to reverse established inhibitors to FVIII.